Neal D. Shore, MD, FACS, presented “GRU Challenging Case: Androgen Deprivation Therapy” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Shore, Neal D. “GRU Challenging Case: Androgen Deprivation Therapy” January 23rd, 2020. Accessed Dec 2025. https://grandroundsinurology.com/case-1-androgen-deprivation-therapy/
GRU Challenging Case: Androgen Deprivation Therapy – Summary:
Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and Atlantic Urology Clinics, leads a panel discussion the physiological and economic factors impacting the ADT selection process. Along with panelists Raoul Concepcion, MD, Michael Cookson, MD, Lawrence Karsh, MD, and Thomas Keane, MD, Dr. Shore emphasizes the impact of the current volume-based and economically incentivized model of treatment and how this can restrict urologists in terms of ADT options. They also discuss the physiological impacts of drug-drug interactions, alternate modes of administration, and the complex prospect of an oral alternative.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Shore led this panel during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Neal D. Shore, MD, FACS, is the Medical Director at Carolina Urologic Research Center in Myrtle Beach, South Carolina. Dr. Shore also serves as a Clinical Urology Specialist at Atlantic Urology Specialists, LLC, also in Myrtle Beach, South Carolina. He is the Director of START GU Oncology Center of Excellence at the START Center for Cancer Research. He is an internationally recognized expert in systemic therapies for patients with advanced urologic cancers of the prostate, kidney, and bladder.
